1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On September 14, 2026, Hyperliquid Strategies Inc and Chardan Capital Markets LLC signed Amendment No. 3 to their ChEF Purchase Agreement, replacing the definition of VWAP Purchase Price. After the first 160,000,000 shares are sold under the agreement, the company's VWAP-based and Intraday VWAP sales are priced at 98.5% of VWAP, and Off-Hour VWAP sales at 97.0% of VWAP. The filing does not state the number of shares expected to be sold, so its effect on existing shareholders cannot be measured from this document.
Amendment No. 3 dated September 14, 2026, amends the ChEF Purchase Agreement dated October 22, 2025, with Chardan Capital Markets LLC.
After the first 160,000,000 shares are sold, VWAP and Intraday VWAP purchases are priced at 98.5% of the VWAP over the applicable period.
Off-Hour VWAP purchases are priced at 97.0% of the VWAP; the amendment supersedes Amendment No. 2 dated September 14, 2026.
On September 14, 2026, Tyra Biosciences agreed to sell 9,079,000 shares of common stock and pre-funded warrants for 9,078,529 shares, with gross proceeds expected to be approximately $400.0 million before underwriting discounts and offering expenses. The offering is expected to close on September 15, 2026, and the company plans to use the net proceeds, together with existing cash, to advance its dabogratinib 3x3 development strategy, support preclinical and discovery programs, and fund working capital and general corporate purposes. Issuing these shares and warrants will dilute existing shareholders.
Offering of 9,079,000 common shares at $22.03 per share, plus pre-funded warrants for 9,078,529 shares at $22.029 per warrant
Underwriters agreed to buy the shares at $20.7082 per share; gross proceeds expected to be approximately $400.0 million
Closing expected September 15, 2026; proceeds targeted at dabogratinib 3x3 in LG-UTUC, IR NMIBC and achondroplasia
Calumet, Inc. entered into an amendment to its credit agreement on September 11, 2026, increasing lender commitments from $500.0 million to $600.0 million, subject to borrowing base limitations. A related amendment to its Monetization Master Agreement with J. Aron & Company LLC was made to permit the larger credit facility. The filing does not state the reasons for the change or any effect on earnings, and shareholders can expect more borrowing capacity under the facility.
Credit agreement commitments rise from $500.0 million to $600.0 million, subject to borrowing base limitations
Eleventh Amendment to the Third Amended and Restated Credit Agreement dated September 11, 2026, with Bank of America, N.A. as administrative agent
Fourth Amendment to the Monetization Master Agreement with J. Aron & Company LLC, dated September 11, 2026, permits the increase
Filed under Items 1.01, 2.03 and 9.01; signed by David Lunin, Executive Vice President and Chief Financial Officer, on September 14, 2026
Clean Energy Technologies received $150,000 in net funding from Walnut Capital through a convertible promissory note with a $166,500 principal amount, closed September 9, 2026. The note matures September 8, 2027, carries a one-time 12% interest charge, and can convert into common stock after default at 85% of the lowest closing bid price over the prior ten trading days, which could add dilution for shareholders.
Principal amount of $166,500 for a purchase price of $150,000, closed September 9, 2026
Note matures September 8, 2027, with a one-time 12% interest charge and 10 monthly payments of $18,648 starting December 8, 2026
Conversion after default at 85% of the lowest closing bid price in the prior ten trading days; holder fees of $1,500 deducted per conversion
Proceeds required to be used for general working capital; note sold without registration under Section 4(a)(2)
On September 14, 2026, Plains All American Pipeline, L.P. (PAA), a wholly owned subsidiary of PAGP, completed a public offering of $700 million of 6.750% Series A notes and $800 million of 7.000% Series B notes, both due December 15, 2056. The notes are unsecured, rank junior to PAA's existing and future senior debt, and are not guaranteed by PAA's subsidiaries. The filing also provides unaudited pro forma 2025 results that show revenue slightly higher but per-share net income from continuing operations lower than reported, reflecting the EPIC Crude Holdings acquisitions.
Series A: $700 million, 6.750% junior subordinated notes due December 15, 2056; interest first payable June 15, 2027.
Series B: $800 million, 7.000% junior subordinated notes due December 15, 2056; rates may reset on December 15, 2036 and every five years after.
Pro forma 2025 revenue of $44,464 million versus $44,262 million historical; net income per Class A share of $0.68 versus $0.77 historical.
Underwriters were J.P. Morgan Securities LLC, Citigroup Global Markets Inc., Mizuho Securities USA LLC, MUFG Securities Americas Inc. and Truist Securities, Inc.
On September 8, 2026, Odyssey and American Ocean Minerals (AOM) amended their note purchase agreement, including a $500,000 initial note that AOM will buy on September 9, 2026. The amendment allows further advances beyond the previously stated maximums, caps each note category at $5.0 million unless AOM agrees otherwise, and expands permitted use of proceeds to expenses incurred through the merger. The notes are secured by substantially all of Odyssey's assets, so the added financing increases the claims ranked ahead of shareholders.
Amendment dated September 8, 2026 provides for an additional $500,000 Initial Note purchased by AOM on September 9, 2026.
Notes bear 8.0% annual interest, rising to 11.0% after an interest payment default, and are secured by substantially all of Odyssey's assets.
Principal and accrued interest are due on the earlier of April 8, 2027, or the closing of the merger under the agreement dated April 8, 2026.
AOM bought a $700,000 Pre-Closing Note on May 28, 2026; each note category is capped at $5.0 million unless AOM agrees in writing.
On September 14, 2026, Amazon closed the sale of four series of notes with a total public offering price of £4.242 billion and estimated net proceeds of about £4.235 billion before offering expenses. The notes carry coupons from 5.200% to 6.650% and mature between 2029 and 2045, so the filing shows new long-term debt that Amazon will need to repay and service.
Four series: 5.200% notes due 2029 (£1.25 billion), 5.550% due 2032 (£1 billion), 6.250% due 2038 (£1 billion), 6.650% due 2045 (£1 billion)
Aggregate public offering price of £4.242 billion; estimated net proceeds of about £4.235 billion before offering expenses
Sold under an Underwriting Agreement dated September 9, 2026, and registered on a Form S-3 filed February 6, 2026
VolitionRX prepaid in cash the outstanding principal of its $7.5 million senior secured convertible note issued to Lind Global Asset Management XII LLC, with the prepayment made on September 11, 2026, and the company says no further amounts remain outstanding under that note. The company says the prepayment prevents further potential dilution to stockholders from the note, and the separate $2.4 million 2026 Note remains in effect.
Prepayment of approximately $422,000 made September 11, 2026 under Section 1.4.1 of the 2025 Note
The $7.5 million 2025 Note, dated May 20, 2025, is fully satisfied; the 2026 Note remains outstanding at $2,041,667 per the press release
CEO Cameron Reynolds said the note was retired more than eight months ahead of its originally scheduled maturity
AIM ImmunoTech Inc. exchanged approximately $400,000 of a November 18, 2025 promissory note held by Streeterville Capital, LLC into 1,749,434 shares of common stock at an average conversion price of about $0.228 per share. The transactions were carried out through two exchange agreements signed September 8 to September 9, 2026, and the shares were issued under a Securities Act exemption for exchanges with an existing holder. Because the new shares add to the outstanding share count, existing shareholders' ownership percentages are diluted, although the filing does not state the total share count.
Debt converted: approximately $400,000 of the Promissory Note dated November 18, 2025
Shares issued: 1,749,434 shares of common stock at an average conversion price of about $0.228 per share
Agreements dated September 8 to September 9, 2026, with Streeterville Capital, LLC; stockholders approved the conversion at a July 15, 2026 special meeting
Shares issued under Section 3(a)(9) of the Securities Act, with no commission paid for the exchange
Plains All American Pipeline completed a public offering of $700 million of 6.750% Series A notes and $800 million of 7.000% Series B notes, both due December 15, 2056. The notes are unsecured and rank junior to PAA's existing and future senior debt, so holders would be paid after senior creditors, and no subsidiaries guarantee them. The filing shows the company is adding $1.5 billion in debt-like obligations, with interest rates that can reset in 2031 and 2036, subject to a floor at the initial rate.
Series A: $700 million, 6.750% coupon, due December 15, 2056; rate can adjust December 15, 2031 and every five years after.
Series B: $800 million, 7.000% coupon, due December 15, 2056; rate can adjust December 15, 2036 and every five years after.
Interest is payable June 15 and December 15, starting June 15, 2027; rates cannot reset below the initial rate.
Underwriting agreement dated September 9, 2026 with J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and others; notes sold under a Form S-3 shelf filed September 6, 2024.
Genasys Inc. entered into a First Amendment to its loan agreement with Maran Partners Fund, LP, dated September 14, 2026, and reported it under Item 2.03 as a direct financial obligation. The filing does not state the amendment's amount, interest rate, maturity or changed terms in the text provided, so shareholders cannot yet judge its size or cost from this document.
Amendment is dated September 14, 2026, between Genasys Inc. and Maran Partners Fund, LP (Exhibit 10.1).
The filing is made under Items 1.01, 2.03 and 9.01; the Item 1.01 disclosure it incorporates is not included in the text provided.
No loan amount, interest rate or revised repayment terms are stated in the text provided.
Filing was signed by Chief Financial Officer Cassandra L. Hernandez-Monteon.
American Tower completed a registered offering of $1.6 billion in senior unsecured notes across three maturities, with net proceeds of about $1,579.9 million. The company plans to use the proceeds to repay $600.0 million of 1.450% notes due 2026, repay borrowings under its $6.0 billion revolving credit facility, and for general corporate purposes. The new debt adds to the company's obligations, with interest rates from 5.300% to 5.750%.
Three tranches: $500.0 million 5.300% notes due September 15, 2031; $500.0 million 5.560% notes due September 15, 2033; $600.0 million 5.750% notes due September 15, 2036
Net proceeds of approximately $1,579.9 million after commissions and estimated expenses
Proceeds earmarked to repay $600.0 million of 1.450% notes due 2026 and revolver borrowings under the $6.0 billion facility
Interest is payable semi-annually beginning March 15, 2027; the notes are issued under a trustee, U.S. Bank Trust Company, National Association
First Citizens BancShares closed a public offering of 300,000 depositary shares, each a 1/100th interest in its new 7.500% Non-Cumulative Perpetual Preferred Stock, Series F, following a September 9, 2026 underwriting agreement. The new preferred ranks ahead of common stock and junior securities on dividends and liquidation, and carries no maturity date. Dividends are non-cumulative and payable only when declared by the board, so holders of common stock are not directly affected by the offering itself.
Offering of 300,000 depositary shares, each representing 1/100th of a $100,000 Series F preferred share, or $1,000 per depositary share; offering closed September 14, 2026
Dividend rate of 7.500% per annum until September 15, 2031, then resets to the five-year treasury rate plus 2.894%
Company may redeem on or after September 15, 2031, or within 90 days after a Regulatory Capital Treatment Event, subject to Federal Reserve approval
Holders elect two directors only if dividends are unpaid for periods totaling 18 months
Oxford Square Capital Corp. notified the trustee for its 5.50% Notes due 2028 that it will redeem $15 million of the $80.5 million outstanding principal on October 14, 2026. Holders will receive $25 per Note plus accrued and unpaid interest from July 31, 2026, which is a routine partial redemption that reduces the amount of Notes outstanding.
Redemption of $15,000,000 principal amount of the 5.50% Notes due 2028 (NasdaqGS: OXSQG)
Redemption date is October 14, 2026; $80.5 million of Notes were outstanding before the redemption
Redemption price is $25 per Note plus accrued and unpaid interest from July 31, 2026
Yarrow Bioscience entered an underwriting agreement on September 10, 2026, to sell 5,769,231 common shares at $26.00 per share, and the underwriters exercised in full their option to buy 865,384 more shares on September 11, 2026. The company expects net proceeds of about $161.8 million, with closing expected on September 14, 2026. The sale adds new shares outstanding, which dilutes existing shareholders, and directors and executive officers agreed to a 60-day lock-up on selling their shares.
Base offering of 5,769,231 shares at $26.00 per share, underwritten by Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC
Underwriters exercised in full their 30-day option on September 11, 2026, for up to 865,384 additional shares
Expected net proceeds of about $161.8 million after underwriting discounts and estimated offering expenses
Offering made under a Form S-3 shelf registration effective August 19, 2026; closing expected September 14, 2026; directors and executive officers subject to a 60-day lock-up
Onconetix agreed on September 11, 2026 to lend up to $5.0 million to Realbotix, LLC, the target of its pending all-stock acquisition, with $2.5 million advanced at signing. The loan is non-interest bearing until the acquisition closes or is terminated, and the balance is cancelled at closing, which reduces the cash Onconetix must hold at closing. For shareholders, the filing shows the financing terms but no change to the acquisition's status, which still requires Onconetix shareholder and regulatory approvals.
Loan of up to $5.0 million to Realbotix, with $2.5 million advanced on September 11, 2026; note matures September 11, 2027
Note is non-interest bearing until the Share Exchange Agreement closes or terminates; 12% annual interest accrues if terminated
At closing, the note is cancelled and the required Net Cash at Closing rises by $500,000 plus the outstanding principal
Realbotix Corp. guarantees the note; closing requires at least $12.5 million in Net Cash
HealthStream entered into a Second Amendment to its revolving credit agreement with Truist Bank as administrative agent, keeping the $50 million facility on terms consistent with the prior agreement. The amendment extends the facility's maturity to September 10, 2031 and sets initial interest margins and a commitment fee, giving the company continued access to revolving credit under unsecured terms.
Revolving loans up to $50 million, with $5 million sublimits for swingline loans and standby letters of credit
Credit facility matures September 10, 2031; the company can seek to increase availability by up to $25 million, subject to lender commitments
Initial applicable margins of 0.50% for base rate loans and 1.50% for SOFR loans; initial commitment fee of 20 basis points per annum
Financial covenants require a net funded debt leverage ratio of not more than 3.00 to 1.00 and an interest coverage ratio of not less than 3.00 to 1.00
XBP Global Holdings agreed on September 11, 2026 to sell 2,275,245 common shares in a private placement to accredited investors at a weighted price of about $2.66 per share, for gross proceeds of about $6.05 million. Insiders, including the CEO, CFO, and affiliates of the Executive Chairman and a board member, were among the buyers, which the company disclosed.
Shares sold at a weighted price of about $2.66; gross proceeds of about $6.05 million, with closing expected on or before September 15, 2026
CEO Andrej Jonovic bought 31,500 shares and CFO Dejan Avramovic bought 8,833 shares; the remaining shares were sold at $2.55
Company must file a resale registration statement by September 22, 2026; officers, directors and certain stockholders agreed to a lock-up of up to 60 days after closing
Future Vision II Acquisition Corp. issued a $65,000 non-interest-bearing promissory note to its sponsor, Hwei Super Speed Co., Ltd., to fund a one-month extension of its deadline to complete a business combination, moving the date from September 13, 2026 to October 13, 2026. The note is forgiven if no business combination is completed, and the company states there is no assurance it will close a deal by October 13, 2026.
Promissory note of $65,000 issued September 10, 2026 to sponsor Hwei Super Speed Co., Ltd.
Business combination deadline extended from September 13, 2026 to October 13, 2026
August 2026 extension redemptions paid at $11.03 per share
Company continues to pursue its merger with MicroTouch Technology Inc. under a January 16, 2026 agreement
Eos Energy said the Federal Financing Bank funded an $87,018,601 advance under the company's DOE-guaranteed loan on September 10, 2026. The company says the advance reimburses 80% of eligible costs at its Thorn Hill facility in Warrendale, Pennsylvania, and brings total drawings under the DOE facility to approximately $178 million since 2024, which means the company's debt obligations rise by the amount drawn.
Third advance of $87,018,601 funded September 10, 2026, after a request delivered August 24, 2026
Advance reimburses 80% of eligible costs for the Thorn Hill facility; total drawn under the DOE facility is approximately $178 million
Line 2 entered commercial production in June 2026; with line 1 relocated to Thorn Hill, subject to lender approvals, the company expects about 4 GWh of annual capacity
Enbridge Inc. sold 44,735,000 common shares on September 14, 2026, under an underwriting agreement dated September 10, 2026, raising approximately CDN$3.0 billion in gross proceeds before underwriting commissions and expenses. The offering included an over-allotment option for 5,835,000 additional shares, which the underwriters exercised in full, and it increases the number of shares outstanding for existing shareholders.
Underwriters bought 38,900,000 common shares on a bought deal basis at CDN$66.85 per share
Underwriters exercised in full their option to buy 5,835,000 additional shares to cover over-allotments
Total shares issued on September 14, 2026: 44,735,000; gross proceeds approximately CDN$3.0 billion
Offered under a shelf registration filed August 1, 2025, with a prospectus supplement dated September 10, 2026
Cabaletta Bio said holders exercised warrants from its June 2025 underwritten public offering, bringing aggregate gross proceeds to approximately $128.2 million through the September 12, 2026 expiration date. Most of that total, 46,011,900 warrants for approximately $115.0 million, was exercised from July 1, 2026 through expiration. For shareholders, the exercises add cash to the company at a fixed exercise price of $2.50 per share.
Warrants issued in the June 2025 offering: 53,090,190, each with an exercise price of $2.50 per whole share
From July 1, 2026 through September 12, 2026: 46,011,900 warrants exercised for approximately $115.0 million in gross proceeds
Total gross proceeds from exercises through the expiration date: approximately $128.2 million, including $13.2 million from 5,275,100 warrants exercised through June 30, 2026
On September 4, 2026, Bally's New York Operating Company entered a loan agreement with WhiteHawk Capital Partners providing $400 million in closing date term loan commitments and $160 million in delayed draw commitments. The loans will fund pre-construction costs for the Bally's Bronx project and general corporate purposes, and they carry a rate of Term SOFR plus 8.50% and are secured by substantially all assets of the borrowing entities. The company said the financing keeps the Bronx project on schedule and adds liquidity, but it adds secured debt at a high interest spread.
Closing date term loan commitments of $400 million and delayed draw term loan commitments of $160 million, under an agreement dated September 4, 2026
Interest at Term SOFR plus 8.50% per annum, subject to a customary floor; loans mature 18 months after initial funding
Loans guaranteed by Bally's New York Guarantors and secured by substantially all assets of the Bally's New York Loan Parties, subject to exceptions
Initial funding is subject to regulatory approval and is expected to close in the third quarter of 2026
On September 9, 2026, Addentax Group Corp. agreed to sell 520,834 shares of common stock to investor Mr. Chan Chun Hong at $4.80 per share, for gross proceeds of about $2.5 million. The company plans to use the net proceeds for general corporate purposes, including working capital and potential strategic investments. The closing is subject to customary conditions, and the shares are being sold without SEC registration under Regulation S, which adds new shares outstanding for existing shareholders.
Shares offered: 520,834 shares of common stock at $4.80 per share
Gross proceeds: about $2.5 million, with closing subject to customary conditions
Investor: Mr. Chan Chun Hong, a non-U.S. person, in an offshore transaction under Regulation S
Use of proceeds: general corporate purposes, including working capital and potential strategic investments
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.